Search Results for citation:"89 FR 105052"

Found 2 results

Search Results: citation:"89 FR 105052"

💰 Only
Oldest Newest
  • 2024-30650 — Office of Child Care; Statement of Organization, Functions, and Delegations of Authority; Correction
    Type:Notice
    Citation:89 FR 105052
    Reading Time:less than a minute

    The Administration for Children and Families (ACF) released a notice correcting a previous document about changes to the Office of Child Care. Published on December 4, 2024, the document mistakenly contained an incorrect code related to the addition of a Regional Operations Division. This correction specifies that the Regional Operations Division will oversee and guide the ten OCC Regional Offices and ensure coordination with central office planning.

    Simple Explanation

    The ACF fixed a mistake in their earlier note that talked about changes in how they organize themselves to better help kids. They made sure everyone understands that there's a special team whose job is to watch over and guide other teams to make a good plan together.

  • 2024-30334 — Statement of Organization, Functions, and Delegations of Authority
    Type:Notice
    Citation:89 FR 105052
    Reading Time:about 6 minutes

    The Food and Drug Administration (FDA) has announced a reorganization of its Center for Drug Evaluation and Research (CDER), specifically within the Office of Surveillance and Epidemiology (OSE) and the Office of New Drugs (OND). This reorganization aims to enhance their ability to support the FDA's mission by improving drug safety and management, addressing drug development for rare diseases, opioids, and other critical areas. The changes include creating several new offices and divisions to streamline operations and respond to legislative requirements. This structure was approved by the Secretary of Health and Human Services and is detailed in the FDA's Staff Manual Guide available online.

    Simple Explanation

    The FDA is changing how they organize their teams that help make sure medicines are safe and good for people, especially focusing on special and serious medicines. They're setting up new groups to make their work faster and follow new rules, but it's not clear how this affects money or how these new teams will work exactly.